The randomized controlled trials (RCTs) incorporating anti-CD38 mAbs with IMiDs and/or PIs, including CANDOR, IKEMA, APOLLO, and ICARIA-MM, have demonstrated promising outcomes for RRMM patients in different risk populations and refractory states, highlighting that anti-CD38-based therapies are efficacious and safe treatment options for patients with RRMM.32–35. Here, CD38 is linked to Miyoshi myopathy.